Scientific Health Development

About The Fund

Scientific Health Development (SHD) is a venture capital firm that specializes in early-stage investments in the realm of healthcare, focusing specifically on life sciences, medical technologies, and wellness sectors. Established in 2006 in Dallas, Texas, SHD targets medtech companies based in the U.S. that aim to address unmet clinical needs. SHD's mission is to foster innovation by investing in technologies that can enhance patient outcomes and simultaneously reduce economic burdens on the healthcare system. The firm's investment strategy centers on companies that not only have innovative technology but also demonstrate the potential for quickly adoptable solutions. SHD distinguishes itself by providing startups with a relatively modest funding requirement—specifically, their investment size ranges uniformly at $19,730,000. This singular investment size reflects SHD's focused approach, which is tailored to medtech enterprises with clear, attainable, near-term value inflection points that could lead to strategic exits. The firm's history is rooted in the successful investment in the Palmaz stent, recognized as the world's first coronary stent, by one of its founders, Philip Romano. Along with Stuart Fitts, they moved from angel investing to establishing SHD, a dedicated healthcare investment firm, in 2006. Andrew Offer, who was brought on board in 2007, has bolstered the firm's financial expertise, specifically in healthcare valuation and reimbursement analysis. Over 15 years, SHD has grown to become a prominent early-stage medtech venture capital firm. With a team that brings together diverse skills and experiences, SHD has managed multiple fund portfolios and presents a differentiated investment opportunity. By investing in medical device startups, SHD offers its limited partners an exposure to the early-stage private sector, which is insulated from the short-term volatility of public markets and benefits from significant Qualified Small Business tax advantages. The investment focus is primarily on software, IT and TMT areas, biotech, medical devices and hospital services, healthcare and wellness, life sciences, and mobile sectors.